CRISPR/Cas-9 and its therapeutic applications in Onco-viral diseases
A promising tool in cancer management
Keywords:
CRISPR/Cas9, cancer therapy, cancer immunotherapy, cancer-associated viruses, gene therapy-approved productsAbstract
The CRISPR/Cas9 technique is one of the gene-editing tools. The CRISPR/Cas9 method is favoured by many due to its high degree of adaptability and precision when cutting and pasting DNA. It makes it possible to carry out genetic engineering on an unprecedented scale at a very low cost, which is one of the reasons why it is so popular. It differs from previous methods of genetic engineering in that it permits the addition or deletion of multiple genes simultaneously. Additionally, it is unique in that it is not species-specific, allowing it to be applied to organisms that were previously resistant to genetic engineering. CRISPR/Cas9 has emerged as a potent strategy for altering the genome, and it has been extensively utilized in a variety of cell lines. CRISPR/Cas9 creation of cell and animal models laid the groundwork for the clinical trials that might have treated the tumor. The technology of genome editing through CRISPR-Cas9 holds great promise for preventing tumor migration, invasion, and even treatment. However, its clinical application is constrained by the possibility of an off-target effect, necessitating an effective ethical review. The research and limitations of cancer clinical trials are discussed, as are the molecular mechanisms of CRISPR/Cas9.
Downloads
References
Sherkow JS. Law, history and lessons in the CRISPR patent conflict. Nature biotechnology. 2015;33(3):256.
van Erp PB, Bloomer G, Wilkinson R, Wiedenheft B. The history and market impact of CRISPR RNA-guided nucleases. Current opinion in virology. 2015;12:85-90.
Redman M, King A, Watson C, King D. What is CRISPR/Cas9? Archives of Disease in Childhood-Education and Practice. 2016;101(4):213-5.
Morange M. What history tells us XXXVII. CRISPR-Cas: The discovery of an immune system in prokaryotes. Journal of biosciences. 2015;40(2):221-3.
Moses C, Garcia-Bloj B, Harvey AR, Blancafort P. Hallmarks of cancer: The CRISPR generation. European Journal of Cancer. 2018;93:10-8.
Jubair L, McMillan NA. The therapeutic potential of CRISPR/Cas9 systems in oncogene-addicted cancer types: virally driven cancers as a model system. Molecular Therapy-Nucleic Acids. 2017;8:56-63.
Jiang F, Doudna JA. CRISPR–Cas9 structures and mechanisms. Annual review of biophysics. 2017;46:505-29.
Song G, Jia M, Chen K, Kong X, Khattak B, Xie C, et al. CRISPR/Cas9: a powerful tool for crop genome editing. The crop journal. 2016;4(2):75-82.
Yi L, Li J. CRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2016;1866(2):197-207.
Gaj T, Gersbach CA, Barbas III CF. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends in biotechnology. 2013;31(7):397-405.
Xue W, Chen S, Yin H, Tammela T, Papagiannakopoulos T, Joshi NS, et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature. 2014;514(7522):380.
Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR, et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell. 2014;159(2):440-55.
McKinley K, Cheeseman I, Holland A. CRISPR-Mediated Genome Engineering for Protein Depletion. Google Patents; 2017.
Wen WS, Yuan ZM, Ma SJ, Xu J, Yuan DT. CRISPR‐Cas9 systems: versatile cancer modelling platforms and promising therapeutic strategies. International journal of cancer. 2016;138(6):1328-36.
Maddalo D, Manchado E, Concepcion CP, Bonetti C, Vidigal JA, Han Y-C, et al. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature. 2014;516(7531):423.
Sachdeva M, Sachdeva N, Pal M, Gupta N, Khan I, Majumdar M, et al. CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer. Cancer gene therapy. 2015;22(11):509.
Yin H, Xue W, Anderson DG. CRISPR–Cas: a tool for cancer research and therapeutics. Nature Reviews Clinical Oncology. 2019;16(5):281-95.
Lu Y, Xue J, Deng T, Zhou X, Yu K, Huang M, et al. A phase I trial of PD-1 deficient engineered T cells with CRISPR/Cas9 in patients with advanced non-small cell lung cancer. American Society of Clinical Oncology; 2018.
Xu CL, Cho GY, Sengillo JD, Park KS, Mahajan VB, Tsang SH. Translation of CRISPR genome surgery to the bedside for retinal diseases. Frontiers in Cell and Developmental Biology. 2018;6.
Zhen S, Hua L, Takahashi Y, Narita S, Liu Y-H, Li Y. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9. Biochemical and biophysical research communications. 2014;450(4):1422-6.
Porteus MH, Dann CT. Genome editing of the germline: broadening the discussion. Molecular Therapy. 2015;23(6):980-2.
Reardon S. Gene--editing wave hits clinic: companies prepare to test range of therapies in people. Nature. 2015;527(7577):146-8.
Sharma R, Anguela XM, Doyon Y, Wechsler T, DeKelver RC, Sproul S, et al. In vivo genome editing of the albumin locus as a platform for protein replacement therapy. Blood. 2015;126(15):1777-84.
Wei J, Yan J, Su S, Shao J, Zhao Y, Xu Q, et al. A phase I/II Trial of CRISPR-Cas9-mediated PD-1 knockout Epstein-Barr virus cytotoxic lymphocytes (EBV-CTLs) for advanced stage EBV associated malignancies. American Society of Clinical Oncology; 2018.
Lv J, Li P. Mesothelin as a biomarker for targeted therapy. Biomarker Research. 2019;7(1):18.
Ghosh D, Venkataramani P, Nandi S, Bhattacharjee S. CRISPR–Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics. Cancer cell international. 2019;19(1):12.
Jung I-Y, Lee J. Unleashing the therapeutic potential of CAR-T cell therapy using gene-editing technologies. Molecules and cells. 2018;41(8):717.
Schacker M, Seimetz D. From fiction to science: clinical potentials and regulatory considerations of gene editing. Clinical and translational medicine. 2019;8(1):27.
Daems C, Vanderroost J, Sokal E, Lysy P, editors. Partial CRISPR/Cas9 IL1R1 & IFNGR1 Knock-Down Improves β-cell Survival And Function Under Cytokine-Induced Inflammation. European Society of Pediatric Endocrinology (ESPE); 2019.
Han X, Wang Y, Han W-D. Chimeric antigen receptor modified T-cells for cancer treatment. Chronic diseases and translational medicine. 2018;4(4):225-43.
Shaz S. Contribution of viruses to cancer and its global burden. Glob J Cancer Ther. 2019;5(1):012-5.
Xiao-Jie L, Hui-Ying X, Zun-Ping K, Jin-Lian C, Li-Juan J. CRISPR-Cas9: a new and promising player in gene therapy. Journal of medical genetics. 2015;52(5):289-96.
Yuan M, Webb E, Lemoine NR, Wang YJV. CRISPR-Cas9 as a powerful tool for efficient creation of oncolytic viruses. Viruses. 2016;8(3):72.
Xia A-L, He Q-F, Wang J-C, Zhu J, Sha Y-Q, Sun B, et al. Applications and advances of CRISPR-Cas9 in cancer immunotherapy. J Med Genet. 2019;56(1):4-9.
Yao S, He Z, Chen C. CRISPR/Cas9-mediated genome editing of epigenetic factors for cancer therapy. Human gene therapy. 2015;26(7):463-71.
Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2017: An update. The journal of gene medicine. 2018;20(5):e3015.
Husain S, Han J, Au P, Shannon K, Puri R. Gene therapy for cancer: regulatory considerations for approval. Cancer gene therapy. 2015;22(12):554.
Anjum, A., Siddique, H., Rabaan, A.A., Alhumaid, S., Garout, M., Almuthree, S.A., Halwani, M.A., Turkistani, S.A., Qutob, H., Albayat, H. and Aljeldah, M., 2023. Evaluation of Hematological, Biochemical Profiles and Molecular Detection of Envelope Gene (gp-41) in Human Immunodeficiency Virus (HIV) among Newly Diagnosed Patients. Medicina, 59(1), p.93.
Rehman, W.U., Shah Zeb, S.N., Meo, S.R., Naeem, A., Ullah, F., Ahmed, S.S., Assad Rehman, S.J., Muhammad, T., Ahmad, H., Tanoli, A.H. and Ullah, J., 2022. Abnormalities in Serum Electrolytes in DF, DHF and DSS as Prognostic Indicators for Dengue Severity: A Comparative Model. Pakistan Journal of Medical & Health Sciences, 16(10), pp.386-386.
Zeb, Shah, Saddam Hussain, Nuzhat ul Ain, Muhammad Wajahat, Jawad Ullah, Ahsan Naeem, Kiramat Ullah, and Bibi Salma Tassaduq Naqvi. "Risk Factors, Screening and Seroprevalence of Dengue Virus Antigen (NS1) in Clinically Suspected Patients: A Community-Based Hospital Study." (2022).
Ahmed, Naveed, Kinza Tahir, Sara Aslam, Sara Masood Cheema, Ali A. Rabaan, Safaa A. Turkistani, Mohammed Garout et al. "Heavy Metal (Arsenic) Induced Antibiotic Resistance among Extended-Spectrum β-Lactamase (ESBL) Producing Bacteria of Nosocomial Origin." Pharmaceuticals 15, no. 11 (2022): 1426.
Zeb, Shah, Mariam Mushtaq, Muneeb Ahmad, Waqas Saleem, Ali A. Rabaan, Bibi Salma Zahid Naqvi, Mohammed Garout et al. "Self-Medication as an Important Risk Factor for Antibiotic Resistance: A Multi-Institutional Survey among Students." Antibiotics 11, no. 7 (2022): 842.
Shaz, S. K. "Contribution of viruses to cancer and its global burden." Glob J Cancer Ther 5, no. 1 (2019): 012-015.
Shaz, S. K., N. Ullah, and I. Rafique. "Prevalence of Hepatitis B and C in District Dir Upper, Khyber Pakhtunkhwa, Pakistan." Glob J Clin Virol 4, no. 1 (2019): 8-18.
Noureen, S., Abbas, A., Alam, M., Bibi, M., Wajahat, M., Dur-e-Shahwar, D.- e-S., Ahmad,I., Ahmed, U., Tanveer, A., Sajjad, S., Khurshid, M., & Zeb, S. (2023). The association of diabetes and obesity with severity of dengue fever: An immunopathology update
Published
How to Cite
Issue
Section
Copyright (c) 2023 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
